Prosecution Insights
Last updated: April 19, 2026

Examiner: TINSLEY, BRENDAN THOMAS

Tech Center 1600 • Art Units: 1634

This examiner grants 56% of resolved cases

Performance Statistics

55.6%
Allow Rate
-4.4% vs TC avg
67
Total Applications
+65.0%
Interview Lift
1391
Avg Prosecution Days
Based on 27 resolved cases, 2023–2026

Rejection Statute Breakdown

7.9%
§101 Eligibility
14.2%
§102 Novelty
29.5%
§103 Obviousness
37.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16986954 THERAPEUTIC EXTRACELLULAR VESICLES Final Rejection Ohio State Innovation Foundation
18005511 TROPHOBLAST STEM CELL-LIKE CELLS CAPABLE OF DIFFERENTIATING INTO PLACENTA-CONSTITUTING CELLS, AND METHOD FOR PRODUCING SAME Non-Final OA TOHOKU UNIVERSITY
17767540 CRISPR-MEDIATED HUMAN GENOME EDITING WITH VECTORS Final Rejection Regents of the University of Minnesota
17642244 NUCLEIC ACID SEQUENCE FOR REGULATION OF TRANSGENE EXPRESSION Final Rejection SORBONNE UNIVERSITE
17811403 COMPOSITION FOR INDUCING DIFFERENTIATION INTO INSULIN-PRODUCING CELLS, AND USE THEREOF Final Rejection SEOUL NATIONAL UNIVERSITY HOSPITAL
17779567 Method for Producing Brown Adipocytes Final Rejection Kyoto Prefectural Public University Corporation
18255868 METHODS FOR PURIFICATION OF AAV VECTORS BY AFFINITY CHROMATOGRAPHY Non-Final OA PFIZER INC.
17759327 METHOD FOR CULTURING FACTOR-INTRODUCED CELLS Final Rejection Koji TANABE
18008139 BACTERIAL STRAINS FOR DNA PRODUCTION Non-Final OA ModernaTX, Inc.
16098464 CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY Final Rejection Editas Medicine, Inc.
17790059 GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47 Final Rejection Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
18505543 METHOD OF PRODUCING ANTIBODIES FROM SINGLE PLASMA CELLS Non-Final OA Daro Zist Azma Oxin
18042635 COMPOSITION FOR PROMOTING DIFFERENTIATION OF NEURAL STEM CELLS INTO DOPAMINERGIC NEURONS Non-Final OA SUNGKWANG MEDICAL FOUNDATION
17791113 Decellularized Nerve Graft and Method of Manufacturing the Same Non-Final OA L&C Bio Co., Ltd.
18262959 Compositions and Methods for Treating Hereditary Angioedema Non-Final OA Spark Therapeutics, Inc.
17760658 Product for Therapy and Methods Final Rejection The University of Bristol
17787719 RAT SPERM FREEZING METHOD AND IN VITRO FERTILIZATION METHOD Non-Final OA NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
17998563 METHOD FOR PRODUCING TARGET CELLS, METHOD FOR PRODUCING PRODUCT USING TARGET CELLS, AND SERUM-FREE MEDIUM Non-Final OA MYORIDGE CO. LTD.
17639281 METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES Non-Final OA Exuma Biotech Corp.
17801102 BIOMATERIAL PRESERVING COMPOSITION Non-Final OA GN Corporation Co Ltd
17415642 CRISPR-CAS SYSTEM FOR GENE THERAPY Final Rejection AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (AOUS)

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month